Language
English
Publication Date
1-12-2025
Journal
Neuro-Oncology
DOI
10.1093/neuonc/noae193
PMID
39427326
PMCID
PMC11726257
PubMedCentral® Posted Date
10-19-2024
PubMedCentral® Full Text Version
Post-print
Abstract
The field of immunology has traditionally focused on immune checkpoint modulation of adaptive immune cells. However, many malignancies such as glioblastoma are mostly devoid of T cells and rather are enriched with immunosuppressive myeloid cells of the innate immune system. While some immune checkpoint targets are shared between adaptive and innate immunity, myeloid-specific checkpoints could also serve as potential therapeutics. To better understand the impact of immune checkpoint blockade on myeloid cells, we systematically summarize the current literature focusing on the direct immunological effects of PD-L1/PD-1, CD24/Siglec-10, collagen/LAIR-1, CX3CL1/CX3CR1, and CXCL10/CXCR3. By synthesizing the molecular mechanisms and the translational implications, we aim to prioritize agents in this category of therapeutics for glioblastoma.
Keywords
Humans, Glioblastoma, Myeloid Cells, Immune Checkpoint Inhibitors, Brain Neoplasms, Animals, Immunotherapy, glioblastoma, immune-checkpoint blockade, myeloid cells
Published Open-Access
yes
Recommended Citation
Du, Ruochen; Zhang, Jianzhong; Lukas, Rimas V; et al., "Is Modulation of Immune Checkpoints on Glioblastoma-Infiltrating Myeloid Cells a Viable Therapeutic Strategy?" (2025). Faculty and Staff Publications. 5326.
https://digitalcommons.library.tmc.edu/baylor_docs/5326